Insulet (NASDAQ:PODD) Price Target Raised to $330.00

Insulet (NASDAQ:PODD) had its target price hoisted by JPMorgan Chase & Co. from $280.00 to $330.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Other research analysts also recently issued reports about the company. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Citigroup boosted their target price on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company raised their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.44.

Insulet Stock Performance

PODD opened at $269.34 on Thursday. The company has a fifty day moving average of $251.37 and a 200 day moving average of $220.31. The stock has a market capitalization of $18.89 billion, a price-to-earnings ratio of 46.12, a PEG ratio of 4.18 and a beta of 1.21. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $279.77.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.47% of the stock is owned by insiders.

Hedge Funds Weigh In On Insulet

Several large investors have recently made changes to their positions in the company. Blue Trust Inc. grew its position in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC grew its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Insulet during the 2nd quarter valued at about $32,000. UMB Bank n.a. increased its stake in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.